Retrobulbar Triamcinolone Acetonide Injection in the Treatment of NA-AION

Second Military Medical University

Status and phase: Unknown; Phase 3

Conditions: Optic Neuropathy, Ischemic; Triamcinolone Acetonide

Treatments: Drug: Triamcinolone Acetonide; Drug: placebo

Study type: Interventional

Funder types: Other

Identifiers

NCT02329288

SecondMMU2014

Details and patient eligibility

About

NAION produces an ischemic insult in the optic nerve head presumably due to the hypoperfusion of the short ciliary arteries that supply it.

Intravenous injection of glucocorticoid have proven to be effective in treatment of Nonarteritic Anterior Ischemic Optic Neuropathy,but have some side effects. the investigators believe that offering them Retrobulbar Triamcinolone Acetonide Injection that might halt the progression of the visual acuity and visual field loss if our hypothesis is correct, would greatly improve their chances of avoiding blindness.

Enrollment: 60 estimated patients

Sex: All

Ages: 18 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

Sudden mono ocular vision loss associated with optic disc edema and positive Marcus Gunn (<30 days)

Exclusion criteria

Any eye disease except NAION(Nonarteritic Anterior Ischemic Optic Neuropathy) Neurologic defect Abnormal ESR, CRP, any history of retina or vitreal surgery Severe corneal opacity which makes retina examination impossible

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

60 participants in 2 patient groups, including a placebo group

Triamcinolone Acetonide

Active Comparator group

Description:

40mg/1ml

Treatment:

Drug: Triamcinolone Acetonide

placebo

Placebo Comparator group

Description:

1ml

Treatment:

Drug: placebo